National Clinical Trial To Test Effectiveness Of Antibiotic Treatment For Coronary Artery Disease

Can heart disease -- the nation's number-one killer -- be effectively treated with antibiotics? A national clinical trial directed by the University of Washington and funded through an $11 million grant from the National Institutes of Health (National Heart, Lung and Blood Institute) and Pfizer Corporation will examine the effectiveness of antibiotic treatment for patients with coronary artery disease.

The Azithromycin and Cardiac Events Study (ACES) focuses on the role of a common bacterium, Chlamydia pneumoniae, that has been associated with atherosclerosis in humans. The study will be led by principal investigator

Dr. J. Thomas Grayston, a pioneer in chlamydia research and professor of epidemiology at the University of Washington School of Public Health and Community Medicine. Approximately 27 clinical centers nationwide will participate in the study.

"The idea of giving antibiotics to treat a chronic disease like coronary artery disease is not as farfetched an idea as it once was," said Grayston. "This clinical trial should help prove whether the Chlamydia pneumoniae bacteria plays a role in the cause of complications of atherosclerosis."

Chlamydia pneumoniae is a common cause of respiratory infections, including pneumonia and bronchitis. Nearly every person is infected with the bacteria at some time in life. In the late 1980s, researchers, including Grayston, identified a possible relationship between Chlamydia pneumoniae and heart disease when the bacteria was identified in samples of diseased coronary artery tissue.

Two small trials evaluating the use of antibiotics for patients with coronary artery disease showed some positive indications.

"This large-scale clinical trial will provide substantial evidence about whether antibiotics should be used in the treatment of coronary artery disease," Grayston said.

Participating research centers will enro

Contact: Julie Rathbun
University of Washington

Page: 1 2

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. National Academies News: William H. Foege to receive Public Welfare Medal, Academys highest honor
3. National Academies news: Academy honors 17 for major contributions to science
4. National Academies advisory: Report assesses health implications of perchlorate exposure
5. National Academies Advisory: Jan. 11 public briefing on perchlorate in drinking water
6. National Academies news: Gulf War and Health
7. National survey shows few physicians elected to Congress
8. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
9. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
10. National Academies advisory: Nov. 4-6 Frontiers of Science meeting in Irvine, Calif.
11. National Chemistry Week celebrates health and wellness in Washington, D.C., area

Post Your Comments:

(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government ... ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies and ... opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to ... are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  ARKRAY USA , Inc., ... evidence demonstrating the accuracy of its blood glucose meter ... Resistance, Diabetes and Cardiovascular Disease in Los ... GLUCOCARD ® 01 meter and the Assure ® ... ability to accurately measure glucose levels in blood is ...
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: AGN ) ... New York State Attorney General,s Office ... Act, and other statutes with the Attorney General over the ... cease marketing and selling the now generic version of memantine ... no liability, has released its counterclaims against New ...
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
Cached News: